Table 2.
Cytogenetic and molecular genetic analysis in acute myelogenous leukemia patients with Sweet's Syndrome
| Patient Characteristics | N | Percentage |
|---|---|---|
| Cytogenetic analysis (n=21) | ||
| Diploid cytogenetics | 7 | 33% |
| Complex cytogenetics (≥ 3 chromosomal abnormalities) | 5 | 24% |
| −5/del(5q) (as sole abnormality) | 3 | 14% |
| t(6;9) | 2 | 10% |
| Trisomy 8 | 1 | 5% |
| t(11;17) | 1 | 5% |
| t(15;17) | 1 | 5% |
| t(3;3) | 1 | 5% |
| Karyotype abnormalities constituting “complex cytogenetics” (n=5)1 | ||
| −5/del(5q) | 5 | 100% |
| −3 | 3 | 60% |
| −13/del(13q) | 3 | 60% |
| −7/del(7q) | 2 | 40% |
| −12 | 2 | 40% |
| −17 | 2 | 40% |
| Others2 | 1 each | 20% |
| Molecular genetics analysis | ||
| FLT3 (total tested = 18) | ||
| Internal Tandem Duplication | 4 | 22% |
| D835 | 3 | 17% |
| NPM1 (total tested=7) | 2 | 28% |
| RAS (total tested=13) | 0 | 0 |
| C-KIT (total tested=5) | 0 | 0 |
| CEBPα (total tested=3) | 0 | 0 |
Abbreviations used: CG: cytogenetics; FLT3: fms-related tyrosine kinase 3; NPM1: nucleophosmin 1, RAS: rat sarcoma, C-KIT: mast/stem cell growth factor receptor Kit; CEBPα: CCAAT/enhancer binding protein alpha
1
Complex cytogenetics patients only (n=5)
2
Others: −1, del(6q), −9, −11, −12, −14, −15, del(20q), add(2p), add(3q), add(6q), add7, add(8q), +11, add(16p), add(17p), add(22q)